Added to YB: 2025-09-01
Pitch date: 2025-08-28
IVVD [bullish]
Invivyd, Inc.
+5.24%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
Market Cap
$415.7M
Pitch Price
$1.05
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.59
P/E
-4.82
EV/Sales
3.58
Sector
Biotechnology
Category
growth
Invivyd: Superior COVID Prophylaxis; Eventual Winner Regardless of Trump Admin Anti-Vaccine Actions
IVVD: COVID mAb developer positioned to replace vaccines as prophylaxis standard. VYD2311 shows 17x higher potency than current Pemgarda, 70+ day half-life enabling IM administration. FDA aligned on single 12-week pivotal trial vs 6mo for vaccines. $80M cash for trial completion, potential CNPV fast-track. Trump admin vaccine ban rumors drove 84% pop. Sub-$200M valuation despite monopoly position in post-vaccine landscape.
Read full article (10 min)